Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

Fig. 1

PRC2 complex is deregulated in MM in association with cell proliferation. a EZH2, SUZ12, and EED gene expression in BMPCs, patients’ MMCs, and HMCLs. Data are MAS5-normalized Affymetrix signals (U133 plus 2.0 microarrays). Statistical difference was assayed using a t test. b Correlation between EZH2 expression and malignant plasma cell labeling index. Plasma cell labeling index represents the percentage of malignant plasma cells in S phase of the cell cycle. It was investigated using Brdu incorporation and flow cytometry in 101 patients at diagnosis. c Top gene sets significantly associated with high EZH2 expression in MM using GSEA

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us